BBCVirtus LifeSci Biotech Clinical Trials ETF

Grow my money11y track recordRanked #1,587 of 2,960 in this goal

Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.

By Virtus · Launched 2014

Annual Cost

0.65%

#3,297 of 5,562 · average

Fund Size

$45M

#3,678 of 5,562 · mid-size

Return (1Y)Goal

+137.5%

Track Record

11 years

#1,258 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$26,245+162.4%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

LifeSci Biotechnology Clinical Trials Index

What it actually holds

By weight

Concentration

Top 10 holdings = 16.2% of fund✓ well diversified

DREYFUS GOVERNMENT CASH MANAGEDGCXX

3.2%

Erasca Inc

2.2%

Corvus Pharmaceuticals Inc

1.9%

Alumis Inc

1.6%

Rezolute Inc

1.4%

Ventyx Biosciences Inc

1.3%

Enliven Therapeutics Inc

1.2%

RAPT Therapeutics Inc

1.2%

Intellia Therapeutics Inc

1.1%

Ironwood Pharmaceuticals Inc

1.0%

Asset allocation

Stocks

99.9%

Cash

0.1%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

36.0%High

Year-on-year price swings

Max drawdown

-76.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.61Decent risk-adjusted returns

Sortino (3Y)

0.88Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks investment results that correspond to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.
Strategy: Invests primarily in component securities of the LifeSci Biotechnology Clinical Trials Index, which tracks U.S. biotechnology companies with lead drugs in Phase 1, 2, or 3 clinical trials. The Fund aims to replicate the Index's performance by holding its constituents.
Inception date: December 16, 2014
Fund family: Virtus